Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018

Tolerability of integrase inhibitors in a real-life setting

(2017) Judit Peñafiel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents

(2015) Rolando M. Viani et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

(2015) S. Nachman et al.   Journal of the Pediatric Infectious Diseases Society

Virtual support for paediatric HIV treatment decision making

(2014) Kirsty Le Doare et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years

(2013) S. Nachman et al.   CLINICAL INFECTIOUS DISEASES

Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis

(2013) Peter Messiaen et al.   PLoS One

Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study

(2012) P. Monteiro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy

(2008) CA Sabin et al.   HIV MEDICINE